MX2009004635A - Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades. - Google Patents

Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.

Info

Publication number
MX2009004635A
MX2009004635A MX2009004635A MX2009004635A MX2009004635A MX 2009004635 A MX2009004635 A MX 2009004635A MX 2009004635 A MX2009004635 A MX 2009004635A MX 2009004635 A MX2009004635 A MX 2009004635A MX 2009004635 A MX2009004635 A MX 2009004635A
Authority
MX
Mexico
Prior art keywords
diaminodiphenyl sulphone
soluble pharmaceutical
pharmaceutical forms
treatment
various diseases
Prior art date
Application number
MX2009004635A
Other languages
English (en)
Inventor
Jaime Kravzov Jinich
Marina Altagracia Martinez
Luis Camilo Rios Castaneda
Maria De Los Angeles Araceli Daz Ruiz
Original Assignee
Univ Autonoma Metropolitana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Autonoma Metropolitana filed Critical Univ Autonoma Metropolitana
Priority to MX2009004635A priority Critical patent/MX2009004635A/es
Priority to US13/266,892 priority patent/US8680156B2/en
Priority to PCT/MX2009/000105 priority patent/WO2010126349A1/es
Priority to BRPI0925000A priority patent/BRPI0925000B8/pt
Priority to KR1020117028275A priority patent/KR101631945B1/ko
Priority to EP09844101.7A priority patent/EP2425829B1/en
Priority to CA2760017A priority patent/CA2760017C/en
Priority to JP2012508413A priority patent/JP5671010B2/ja
Priority to RU2011145768/15A priority patent/RU2538658C2/ru
Priority to CN200980158985.8A priority patent/CN102548547B/zh
Publication of MX2009004635A publication Critical patent/MX2009004635A/es
Priority to CO11164315A priority patent/CO6470840A2/es
Priority to HK12113527.1A priority patent/HK1172568A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención, tiene por objeto demostrar que se puede preparar una forma farmacéutica soluble de la N,N´-Diamino-difenilsulfona, útil en la obtención de un medicamento optimo para su empleo contra el infarto cerebral, la epilepsia, la lesión traumática de la medula espinal, la lesión cráneo-encefálica, la lepra, las infecciones por pneumocystis carinii y cualquier condición en que se requiera una absorción rápida y completa del compuesto. Como ejemplo representativo de esta aplicación, la disolución de la N,N´-Diamino-difenilsulfona fue evaluada como neuroprotector, en un modelo de infarto agudo cerebral en ratas. En este estudio la N,N´-Diamino-difenilsulfona demostró una prevención significativa del daño cerebral, sin presentarse efectos adversos en los animales. Se muestra también que las formas farmacéuticas solubles preparadas de esta forma, producen concentraciones sanguíneas máximas 30 minutos de la administración por la vía oral e inmediatamente por la vía intravenosa.
MX2009004635A 2009-04-29 2009-04-29 Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades. MX2009004635A (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MX2009004635A MX2009004635A (es) 2009-04-29 2009-04-29 Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.
EP09844101.7A EP2425829B1 (en) 2009-04-29 2009-10-05 Soluble pharmaceutical forms of n,n'-diaminodiphenyl sulphone for optimum use in the treatment of various diseases
PCT/MX2009/000105 WO2010126349A1 (es) 2009-04-29 2009-10-05 Formas farmacéuticas solubles de la n, n'-diaminodifenilsulfona para uso óptimo en el tratamiento de diversas enfermedades
BRPI0925000A BRPI0925000B8 (pt) 2009-04-29 2009-10-05 solução de n,n’-diamino-difenil sulfona e seu uso terapêutico
KR1020117028275A KR101631945B1 (ko) 2009-04-29 2009-10-05 다양한 질병의 치료 용도에 최적인 ｎ,ｎ'-디아미노디페닐 술폰의 가용성 제약 제제
US13/266,892 US8680156B2 (en) 2009-04-29 2009-10-05 Soluble pharmaceutical formulations of N,N′-diaminodiphenyl sulfone for optimal use in the treatment of various diseases
CA2760017A CA2760017C (en) 2009-04-29 2009-10-05 Soluble pharmaceutical forms of n,n'-diaminodiphenyl sulphone for optimum use in the treatment of various diseases
JP2012508413A JP5671010B2 (ja) 2009-04-29 2009-10-05 各種疾患の治療に最適なｎ，ｎジアミノジフェニールスルフォン酸塩の医薬用溶融物
RU2011145768/15A RU2538658C2 (ru) 2009-04-29 2009-10-05 Растворимые лекарственные формы n,n'-диаминодифенилсульфона для оптимального применения в лечении различных заболеваний
CN200980158985.8A CN102548547B (zh) 2009-04-29 2009-10-05 在治疗各种疾病中最佳使用的n,n’-二氨基二苯砜的可溶性药物制剂
CO11164315A CO6470840A2 (es) 2009-04-29 2011-11-29 Formas farmacéuticas solubles de la n, n´-diaminodifenilsulfona para uso óptimo en el tratamiento de diversas enfermedades
HK12113527.1A HK1172568A1 (en) 2009-04-29 2012-12-28 Soluble pharmaceutical forms of n,n-diaminodiphenyl sulphone for optimum use in the treatment of various diseases nn-

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2009004635A MX2009004635A (es) 2009-04-29 2009-04-29 Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.

Publications (1)

Publication Number Publication Date
MX2009004635A true MX2009004635A (es) 2010-10-29

Family

ID=43032353

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004635A MX2009004635A (es) 2009-04-29 2009-04-29 Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.

Country Status (12)

Country Link
US (1) US8680156B2 (es)
EP (1) EP2425829B1 (es)
JP (1) JP5671010B2 (es)
KR (1) KR101631945B1 (es)
CN (1) CN102548547B (es)
BR (1) BRPI0925000B8 (es)
CA (1) CA2760017C (es)
CO (1) CO6470840A2 (es)
HK (1) HK1172568A1 (es)
MX (1) MX2009004635A (es)
RU (1) RU2538658C2 (es)
WO (1) WO2010126349A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101875705B1 (ko) * 2011-12-07 2018-07-06 삼성전자주식회사 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물
KR20160047318A (ko) * 2014-10-22 2016-05-02 삼성전자주식회사 다프손을 포함하는, 개체의 부위에서 혈관신생을 자극시키기 위한 조성물 및 그의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721242A (en) * 1993-06-17 1998-02-24 Hoffmann-La Roche Inc. Antibiotic combination
RU2200550C2 (ru) * 1999-10-29 2003-03-20 Научно-исследовательская лаборатория иммунохимиотерапии лепры и иммунотропных средств с клиникой и опытно-экспериментальным производством Новые лекарственные формы димоцифона в терапии лепры, зудящих и аллергодерматозов, герпетиформного дерматита дюринга
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
MXPA03006549A (es) * 2003-07-22 2004-03-18 Univ Autonoma Metropolitana Uso de la dapsona como neuroprotector en el infarto cerebral.
US20060204526A1 (en) * 2003-08-13 2006-09-14 Lathrop Robert W Emulsive composition containing Dapsone
WO2009108147A1 (en) * 2008-02-27 2009-09-03 Qlt Usa, Inc. Dapsone to treat rosascea

Also Published As

Publication number Publication date
EP2425829A4 (en) 2012-10-17
RU2011145768A (ru) 2013-06-10
EP2425829B1 (en) 2015-07-22
JP2012525379A (ja) 2012-10-22
CN102548547B (zh) 2014-10-15
WO2010126349A1 (es) 2010-11-04
KR20150124460A (ko) 2015-11-06
BRPI0925000B1 (pt) 2020-08-18
KR101631945B1 (ko) 2016-06-20
US20120157541A1 (en) 2012-06-21
BRPI0925000B8 (pt) 2021-05-25
JP5671010B2 (ja) 2015-02-18
CN102548547A (zh) 2012-07-04
US8680156B2 (en) 2014-03-25
CA2760017A1 (en) 2010-11-04
CA2760017C (en) 2016-02-23
HK1172568A1 (en) 2013-04-26
RU2538658C2 (ru) 2015-01-10
EP2425829A1 (en) 2012-03-07
CO6470840A2 (es) 2012-06-29

Similar Documents

Publication Publication Date Title
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
WO2006055954A3 (en) Steroid formulation and methods of treatment using same
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
EP2392363A3 (en) Drug coated expandable devices
WO2009043476A3 (en) Neuromedin s as a therapeutic agent
NZ605469A (en) Nalbuphine-based formulations and uses thereof
RU2016106829A (ru) Применение ингибиторов ацетил-СоА карбоксилазы для лечения обыкновенных угрей
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
WO2008149802A1 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
HRP20161197T1 (hr) 24-norudca za liječenje autoimunog hepatitisa
SG11201408323RA (en) Prophylactic and/or therapeutic agent for mild cognitive impairment
DE602005021115D1 (de) Verfahren und zusammensetzungen zur oralen fts-abgabe
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
MX2009004635A (es) Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.
ATE506941T1 (de) Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon
WO2007144081A3 (de) Raucherentwöhnungs-kombinationswafer
EP2272537A3 (en) Salts of conjugated psychotropic drugs and processes of preparing same
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
WO2006089120A3 (en) Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury
WO2009008461A1 (ja) 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物
WO2007144889A3 (en) Treatment of neurofibromatosis
EP1889615A3 (en) Formulations for oral administration with a health promoting effect on the osteoarticular and muscleskeleton apparatus
DE602006016168D1 (de) 1,3,5-triazepin-dionen zur Behandlung von Malaria

Legal Events

Date Code Title Description
FG Grant or registration